Ani Pharmaceuticals Stock Return On Equity

ANIP Stock

USD 56.91 1.05 1.88%

ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Return On Equity	0.04	0.05

As of 11/25/2024, Return On Equity is likely to grow to 0.05.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ANI Pharmaceuticals Company Return On Equity Analysis

ANI Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current ANI Pharmaceuticals Return On Equity

-0.016

Most of ANI Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ANI Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Return On Equity. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		1.0	0.59	0.16	0.94	0.99	0.95	-0.48	-0.18	0.61	0.97	0.09	0.87	0.9	0.67	0.65	-0.81	0.81	0.92	0.88	-0.8	0.83	0.8	0.81	-0.73
Total Stockholder Equity	1.0		0.52	0.15	0.94	0.98	0.96	-0.48	-0.14	0.64	0.95	0.15	0.86	0.91	0.66	0.68	-0.77	0.77	0.9	0.88	-0.76	0.84	0.82	0.81	-0.73
Net Debt	0.59	0.52		0.34	0.44	0.66	0.3	-0.44	-0.21	0.06	0.65	-0.5	0.68	0.39	0.57	-0.06	-0.78	0.9	0.72	0.61	-0.68	0.38	0.16	0.45	-0.29
Retained Earnings	0.16	0.15	0.34		-0.06	0.18	0.04	-0.89	0.4	0.08	0.09	-0.18	0.24	-0.11	0.2	-0.12	-0.24	0.39	0.24	0.09	-0.1	-0.14	-0.2	-0.16	0.21
Accounts Payable	0.94	0.94	0.44	-0.06		0.92	0.94	-0.31	-0.38	0.56	0.96	0.22	0.77	0.96	0.58	0.75	-0.77	0.62	0.87	0.84	-0.77	0.9	0.91	0.86	-0.85
Total Liab	0.99	0.98	0.66	0.18	0.92		0.91	-0.48	-0.21	0.56	0.97	0.04	0.89	0.88	0.68	0.58	-0.85	0.85	0.94	0.89	-0.83	0.82	0.76	0.8	-0.71
Total Current Assets	0.95	0.96	0.3	0.04	0.94	0.91		-0.39	-0.16	0.71	0.9	0.34	0.78	0.92	0.58	0.79	-0.66	0.59	0.8	0.82	-0.7	0.85	0.89	0.79	-0.79
Common Stock	-0.48	-0.48	-0.44	-0.89	-0.31	-0.48	-0.39		-0.22	-0.37	-0.43	0.01	-0.5	-0.3	-0.42	-0.16	0.42	-0.54	-0.47	-0.42	0.35	-0.24	-0.2	-0.24	0.2
Short Term Debt	-0.18	-0.14	-0.21	0.4	-0.38	-0.21	-0.16	-0.22		0.14	-0.33	0.13	-0.17	-0.37	-0.19	-0.24	0.31	-0.07	-0.27	-0.22	0.61	-0.39	-0.47	-0.39	0.32
Current Deferred Revenue	0.61	0.64	0.06	0.08	0.56	0.56	0.71	-0.37	0.14		0.55	0.28	0.49	0.58	0.34	0.62	-0.11	0.31	0.29	0.5	-0.34	0.5	0.64	0.46	-0.72
Net Receivables	0.97	0.95	0.65	0.09	0.96	0.97	0.9	-0.43	-0.33	0.55		0.06	0.85	0.92	0.66	0.63	-0.84	0.78	0.93	0.89	-0.83	0.86	0.82	0.84	-0.8
Net Tangible Assets	0.09	0.15	-0.5	-0.18	0.22	0.04	0.34	0.01	0.13	0.28	0.06		0.14	0.28	0.03	0.22	0.12	-0.34	-0.06	0.16	0.13	0.28	0.35	0.28	-0.31
Long Term Debt	0.87	0.86	0.68	0.24	0.77	0.89	0.78	-0.5	-0.17	0.49	0.85	0.14		0.77	0.81	0.41	-0.75	0.84	0.82	0.95	-0.79	0.81	0.65	0.82	-0.57
Good Will	0.9	0.91	0.39	-0.11	0.96	0.88	0.92	-0.3	-0.37	0.58	0.92	0.28	0.77		0.54	0.7	-0.66	0.59	0.79	0.86	-0.71	0.95	0.93	0.94	-0.83
Long Term Debt Total	0.67	0.66	0.57	0.2	0.58	0.68	0.58	-0.42	-0.19	0.34	0.66	0.03	0.81	0.54		0.34	-0.64	0.68	0.67	0.74	-0.72	0.59	0.49	0.57	-0.38
Long Term Investments	0.65	0.68	-0.06	-0.12	0.75	0.58	0.79	-0.16	-0.24	0.62	0.63	0.22	0.41	0.7	0.34		-0.35	0.22	0.5	0.55	-0.44	0.71	0.82	0.56	-0.64
Treasury Stock	-0.81	-0.77	-0.78	-0.24	-0.77	-0.85	-0.66	0.42	0.31	-0.11	-0.84	0.12	-0.75	-0.66	-0.64	-0.35		-0.81	-0.96	-0.74	0.8	-0.62	-0.48	-0.61	0.49
Intangible Assets	0.81	0.77	0.9	0.39	0.62	0.85	0.59	-0.54	-0.07	0.31	0.78	-0.34	0.84	0.59	0.68	0.22	-0.81		0.85	0.79	-0.74	0.58	0.38	0.61	-0.37
Property Plant Equipment	0.92	0.9	0.72	0.24	0.87	0.94	0.8	-0.47	-0.27	0.29	0.93	-0.06	0.82	0.79	0.67	0.5	-0.96	0.85		0.82	-0.82	0.73	0.63	0.7	-0.56
Capital Surpluse	0.88	0.88	0.61	0.09	0.84	0.89	0.82	-0.42	-0.22	0.5	0.89	0.16	0.95	0.86	0.74	0.55	-0.74	0.79	0.82		-0.73	0.93	0.72	0.92	-0.67
Short Long Term Debt	-0.8	-0.76	-0.68	-0.1	-0.77	-0.83	-0.7	0.35	0.61	-0.34	-0.83	0.13	-0.79	-0.71	-0.72	-0.44	0.8	-0.74	-0.82	-0.73		-0.67	-0.68	-0.66	0.56
Net Invested Capital	0.83	0.84	0.38	-0.14	0.9	0.82	0.85	-0.24	-0.39	0.5	0.86	0.28	0.81	0.95	0.59	0.71	-0.62	0.58	0.73	0.93	-0.67		0.88	0.98	-0.75
Net Working Capital	0.8	0.82	0.16	-0.2	0.91	0.76	0.89	-0.2	-0.47	0.64	0.82	0.35	0.65	0.93	0.49	0.82	-0.48	0.38	0.63	0.72	-0.68	0.88		0.82	-0.81
Capital Stock	0.81	0.81	0.45	-0.16	0.86	0.8	0.79	-0.24	-0.39	0.46	0.84	0.28	0.82	0.94	0.57	0.56	-0.61	0.61	0.7	0.92	-0.66	0.98	0.82		-0.75
Accumulated Depreciation	-0.73	-0.73	-0.29	0.21	-0.85	-0.71	-0.79	0.2	0.32	-0.72	-0.8	-0.31	-0.57	-0.83	-0.38	-0.64	0.49	-0.37	-0.56	-0.67	0.56	-0.75	-0.81	-0.75

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict ANI Pharmaceuticals

Return On Equity Over Time

ANI Total Stockholder Equity

Total Stockholder Equity

454.39 Million

At this time, ANI Pharmaceuticals' Total Stockholder Equity is relatively stable compared to the past year.

Based on the latest financial disclosure, ANI Pharmaceuticals has a Return On Equity of -0.016. This is 99.93% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 94.84% lower than that of the firm.

ANI Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.

ANI Pharmaceuticals is currently under evaluation in return on equity category among its peers.

ANI Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

ANI Fundamentals

	Return On Equity	-0.016
	Return On Asset	0.0125
	Profit Margin	(0.01) %
	Operating Margin	(0.07) %
	Current Valuation	1.69 B
	Shares Outstanding	21.02 M
	Shares Owned By Insiders	11.10 %
	Shares Owned By Institutions	99.67 %
	Number Of Shares Shorted	2.16 M
	Price To Earning	43.35 X
	Price To Book	2.95 X
	Price To Sales	2.15 X
	Revenue	486.82 M
	Gross Profit	177.6 M
	EBITDA	109.32 M
	Net Income	18.78 M
	Cash And Equivalents	63.38 M
	Cash Per Share	3.89 X
	Total Debt	285.67 M
	Debt To Equity	0.85 %
	Current Ratio	3.35 X
	Book Value Per Share	20.74 X
	Cash Flow From Operations	118.96 M
	Short Ratio	11.73 X
	Earnings Per Share	(0.47) X
	Price To Earnings To Growth	1.06 X
	Target Price	78.4
	Number Of Employees	642
	Beta	0.71
	Market Capitalization	1.2 B
	Total Asset	904.42 M
	Retained Earnings	(80.13 M)
	Working Capital	374.34 M
	Current Asset	192.58 M
	Current Liabilities	11.76 M
	Net Asset	904.42 M

About ANI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against ANI Stock

0.4	VRDN	Viridian Therapeutics	Pair Corr
0.35	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.31	GILD	Gilead Sciences	Pair Corr

The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.

The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC